An ampicilEn-sulbactakn combination was conipared with ampicillin alone, chloramphenicol, clindamycin, and metronidazoDe against 272 strains of anaerobic bacteria. Chloramphenicol and ampicillin-sulbactam were the most effective, inhibiting 98 to 99% of strains tested at breakpoint (16 pg/ml). The combination of sulbactam and ampicillin was much more effective than ampiciflin alone against Bacteroidesfragilis strains but did not differ substantially from ampicillin alone against Fusobactetium spp., gram-positive rods, and gram-positive cocci.
Various~-lactamase inhibitors, including sulbactam, clavulanic acid, and UK-38006 have been introduced and tested in vitro (2, 6, 12, 14) and in clinical trials (11, 13) .
Sulbactam is a penicillanic acid sulphone derivative which inhibits the P-lactamases produced by Staphylococcus aureus, Neisseria gonorrhoeae, Haemophilus influenzae, and Bacteroides fragilis (3) . Its pharmacokinetic characteristics in humahs are similar to those of ampicillin and amoxicillin (5 ANTIMICROB. AGENTS CHEMOTHER.
to those found in this study. The other antimicrobial agents generally behaved as expected, although clindamycin showed borderline activity (MIC, 8 p.g/ml) against three of seven strains of Clostridium perfringens. Of note in this study is the variation of resistance patterns among the B. fragilis group species. Although some early studies reported little or no difference in resistance patterns among the various species (1, 10, 15) , in susceptibility testing done at Wadsworth it was noted that the susceptibility of the different species of the B. fragilis group varies widely, specifically in regard to clindamycin and cefoxitin (H. Wexler, W. T. Carter, B. Harris, and S. M. Finegold, Diagn. Microbiol. Infect. Dis., in press). There has been at least one report that the indole-positive members of the B. fragilis group (B. thetaiotaomicron, Bacteroides ovatus, and Bacteroides uniformis) were more resistant than the indolenegative species (B. fragilis, Bacteroides vulgatus, Bacteroides distasonis) (9) . However, this study, as well as others done in our laboratory (Wexler et al., in press) and elsewhere (7), has shown that many strains of B. distasonis consistently show resistance to several antimicrobial agents, including cefoxitin and clindamycin.
In this study, all the members of the B. fragilis group were completely inhibited by breakpoint levels ( Table 1 , footnote c) of ampicillin-sulbactam, chloramphenicol, and metronidazole. Variation among the species was seen in susceptibility to both ampicillin and clindamycin. At breakpoint levels, the percentage of strains susceptible to ampicillin and clindamycin, respectively, were: B. fragilis, 71 and 100%; B. thetaiotaomicron, 19 and 90%o; B. vulgatus, 66 and 50%; B.
ovatus, 22 and 66%; and B. uniformis, 43 and 71%. Because of these differences, varying the proportion of the various species of the B. fragilis group tested has a marked effect upon the total percentage which is susceptible. For example, when the resistances of the B. fragilis group were weighted to reflect the proportions of species actually seen at Wadsworth in 1982, the total resistance of the B. fragilis group to clindamycin was 14% rather than the 20% seen in Table 1 , and susceptibility to ampicillin was 25 rather than 30%. The other agents were all 100% effective against the B. fragilis group at breakpoint, and thus were not similarly affected. When percentages of B. fragilis resistance are compared between different laboratories, great care must be taken to ensure that these and other variables (e.g., testing methods, media, and inoculum size) are taken into account.
